ALNY - ALNYLAM PHARMACEUTICALS, INC.

QQQ $ 598.50 $ -4.01 (-0.67 %)

DIA $ 463.08 $ 2.03 (0.44 %)

SPY $ 662.74 $ -0.81 (-0.12 %)

TLT $ 90.69 $ 0.29 (0.32 %)

GLD $ 382.95 $ 2.70 (0.71 %)

Previous Close

$ 469.36

Open

$ 462.13

Bid

$ 455.65 x 8

Ask

$ 475.00 x 1

Day's Range

$ 457.73 - $ 479.69

52 Week Range

$ 205.87 - $ 484.21

Volume

1,435,825

Average Volume

Market Cap

61.52B

Beta (5Y Monthly)

$ 0.97

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-31-2025	06-30-2025	10-Q
2	05-01-2025	03-31-2025	10-Q
3	02-13-2025	12-31-2024	10-K
4	10-31-2024	09-30-2024	10-Q
5	08-01-2024	06-30-2024	10-Q
6	05-02-2024	03-31-2024	10-Q
7	02-15-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	02-23-2023	12-31-2022	10-K
12	10-27-2022	09-30-2022	10-Q
13	07-28-2022	06-30-2022	10-Q
14	04-28-2022	03-31-2022	10-Q
15	02-10-2022	12-31-2021	10-K
16	10-28-2021	09-30-2021	10-Q
17	08-03-2021	06-30-2021	10-Q
18	04-29-2021	03-31-2021	10-Q
19	02-11-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-06-2020	03-31-2020	10-Q
23	02-13-2020	12-31-2019	10-K
24	10-31-2019	09-30-2019	10-Q
25	08-06-2019	06-30-2019	10-Q
26	05-02-2019	03-31-2019	10-Q
27	02-14-2019	12-31-2018	10-K
28	11-07-2018	09-30-2018	10-Q
29	08-02-2018	06-30-2018	10-Q
30	05-04-2018	03-31-2018	10-Q
31	02-15-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-09-2017	06-30-2017	10-Q
34	05-05-2017	03-31-2017	10-Q
35	02-15-2017	12-31-2016	10-K
36	11-03-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-04-2016	03-31-2016	10-Q
39	02-12-2016	12-31-2015	10-K
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

$1000 Invested In Alnylam Pharmaceuticals ...
10/14/2025 16:30:44

JP Morgan Maintains Overweight on Alnylam ...
10/13/2025 13:53:37

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target ...

HC Wainwright & Co. Reiterates Buy on Alny...
10/10/2025 11:00:54

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintain...

27 Analysts Assess Alnylam Pharmaceuticals...
10/06/2025 22:01:29

Morgan Stanley Maintains Equal-Weight on A...
10/06/2025 13:47:47

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price ...

Stifel Maintains Buy on Alnylam Pharmaceut...
10/06/2025 12:28:51

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $441...

'Alnylam Pulls TV Ad After Trump Crackdown...
10/02/2025 14:48:37

https://www.bloomberg.com/news/articles/2025-10-02/alnylam-pulls-tv-ad-after-trump-crackdown-on-drug-industry-spots?embedded-ch...

Alnylam Begins Global Phase 3 Trial Testin...
10/01/2025 11:36:22

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the first patient has ...

Reported Sunday, Alnylam Pharmaceuticals H...
09/29/2025 06:48:44

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Acro...

Alnylam Pharmaceuticals Announced Earlier ...
09/28/2025 23:36:36

Alnylam Pharmaceuticals today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an ...

$1000 Invested In Alnylam Pharmaceuticals ...
09/26/2025 21:58:22

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis produ...

intellia-highlights-clinical-improvements-with-one-time-dose-of-experimental-drug

Intellia Highlights Clinical Improvements ...
09/25/2025 17:57:31

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of inv...

Beyond The Numbers: 28 Analysts Discuss Al...
09/19/2025 14:01:37

RBC Capital Maintains Outperform on Alnyla...
09/19/2025 13:02:31

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...

Alnylam Joins Illumina And NashBio's Allia...
09/18/2025 13:22:18

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene sile...

B of A Securities Maintains Buy on Alnylam...
09/17/2025 13:19:42

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price targe...

Goldman Sachs Maintains Buy on Alnylam Pha...
09/16/2025 16:38:58

Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target...

'BridgeBio Says Pfizer, Alnylam Aren't Pla...
09/11/2025 18:47:11

https://www.bloomberg.com/news/articles/2025-09-11/bridgebio-says-pfizer-alnylam-aren-t-playing-fair-in-blockbuster-race?embedd...

Evercore ISI Group Maintains Outperform on...
09/11/2025 13:51:05

Evercore ISI Group analyst Liisa Bayko maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the pric...

Reported Earlier, Alnylam Prices Upsized $...
09/10/2025 06:57:45